An interview with: Adetunji T. Toriola, MD, PhD, MPH, Professor of Surgery, Department of Surgery and Division of Public Health Sciences, Washington University School of Medicine and Siteman Cancer Ce
An interview with:
Adetunji T. Toriola, MD, PhD, MPH, Professor of Surgery, Department of Surgery and Division of Public Health Sciences, Washington University School of Medicine and Siteman Cancer Center, St Louis, Missouri, USA
And with:
Elaine R. Mardis, PhD FAACR, Co-executive director of the Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children’s Hospital, Rasmussen Nationwide Foundation Endowed Chair in Genomic Medicine, Professor of Pediatrics, Ohio State University College of Medicine, Columbus OH.
CHICAGO, USA—Breast cancer mortality in American women aged 20-49 dropped significantly between 2010 and 2020, according to research reported at the American Association for Cancer Research 2025 Annual Meeting by epidemiologists from St Louis, Missouri. This was despite a rising incidence of the disease in these younger women.
Peter Goodwin met up with the presenting author of the study, Adetunji T. Toriola MD PhD MPH, Professor of Surgery at Washington University School of Medicine and the Siteman Cancer Center in St Louis.
Elaine Mardis PhD, Co-Executive Director of the Rasmussen Institute for Genomic Medicine and Nationwide Children’s Professor of Pediatrics at Ohio State University College of Medicine, in Columbus, added her comments.
AACR Abstract Title:
“Trends in breast cancer incidence-based mortality among US women aged 20-49 by molecular subtypes and race”
Tags
Related Episodes

Amparo Garcia-Tejedor MD, PhD; 2026 EBCC: Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema
Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema An interview with: Amparo Garcia-Tejedor MD, PhD, Profe

Eline Verreck BSc; 2026 EBCC: Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer
Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer An interview with: Eline Verreck BSc, Erasmus University Medical Centre, Surgical Oncology Department, Rotterd

Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
A seective estrogen degrader out-performed AI’s in ER+ HER- early breast cancer
